Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylaxis of Atopic Dermatitis in High-risk Newborns with SanaCutan Basiscreme
NCT04398758Phase 3Unknown
- Sponsor
- InfectoPharm
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Hydrogel Systems, Transdermal Patches
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of SanaCutan Basiscreme in atopic dermatitis (AD) (2 arms), sponsored by InfectoPharm. Primary endpoint: Cumulative incidence of children with atopic dermatitis at 6 months of age. Status: unknown.
02
Drugs
SanaCutan Basiscreme
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04398758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398758.